Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Quoin Pharmaceuticals received FDA clearance for the first-ever IND in Peeling Skin Syndrome, with a Phase 2/3 study expected to initiate in the second half of 2026. The company also reported conditional FDA approval of the QYLEKI brand name for QRX003 in Netherton Syndrome and secured a U.S. patent allowance for a combination treatment.
Key figures
- Cash
- 10800000
- Net loss 6m
- 10400000
- Net loss q2
- 5400000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.